NERV - The Evolution of a Soup Spoon - Part 1
This is a Pre-Covid, Pre-Fall...Chart Analysis of Minerva Neurosciences
Why? ...you might ask
Because the past predicts the future with some of these stocks. NERV happens to have a unique and fun pattern.
This stock absolutely has a defined pattern that has been getting more aggressive over time.
I didn't reach back further than the PIPE...it MAY even pre-exist the PIPE.
PIPE - basically a modified Cup&Handle where the handle is at an Angle upwards. The PIPE has the flattest, slowest handle.
LADLE - handle gets steeper (the really good technical analysts saw something they liked)
SOUP SPOON - surely, tech-ies flaunted their secret knowledge when it worked out well for them. Those of us less gifted simply copied their homework. Many more people caught on. Handle was at a much more aggressive angle with a fantastic pay-off.
Then something unexpected happened...NERV had a BIG setback with their prize product. It didn't make it across the finish line as was expected. The final Clinical Trial results revealed that it was not effective enough.
It took a nose-dive...from 16 to 3...seemingly ruining its unique little pattern
Did this mean the end for our Soup Spoon?
Check out Part 2...the next one pays off.
Why? ...you might ask
Because the past predicts the future with some of these stocks. NERV happens to have a unique and fun pattern.
This stock absolutely has a defined pattern that has been getting more aggressive over time.
I didn't reach back further than the PIPE...it MAY even pre-exist the PIPE.
PIPE - basically a modified Cup&Handle where the handle is at an Angle upwards. The PIPE has the flattest, slowest handle.
LADLE - handle gets steeper (the really good technical analysts saw something they liked)
SOUP SPOON - surely, tech-ies flaunted their secret knowledge when it worked out well for them. Those of us less gifted simply copied their homework. Many more people caught on. Handle was at a much more aggressive angle with a fantastic pay-off.
Then something unexpected happened...NERV had a BIG setback with their prize product. It didn't make it across the finish line as was expected. The final Clinical Trial results revealed that it was not effective enough.
It took a nose-dive...from 16 to 3...seemingly ruining its unique little pattern
Did this mean the end for our Soup Spoon?
Check out Part 2...the next one pays off.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.